Objectives: Transcatheter aortic valve implantation (TAVI) is a minimally invasive percutaneous procedure for the treatment of elderly patients with symptomatic severe aortic stenosis. The study aimed to determine immediate (in-hospital) and short-term (30-day) outcomes of TAVI with next-generation balloon-expandable Myval transcatheter heart valve (THV) at a single-centre in Iraq. Methods: During January 2019 to January 2024, a total of 100 symptomatic severe aortic stenosis patients who underwent TAVI using Myval THV at Al-Najaf Cardiac Center, Iraq were enrolled. The procedure was done under local anesthesia and conscious sedation via transfemoral approach, using balloon-expandable Myval THV. All patients were followed-up at post-procedure, during hospitalization and thereafter periodically for procedural and clinical outcomes and complications. Results: The mean age of these patients was 73.8 ± 6.5 years and there were equal proportion of male and female patients. Immediate post-procedure and short-term mortality was 1%, while vascular complications, moderate paravalvular leak and overall conduction abnormalities were 11%, 4% and 21%, respectively at 30-day follow-up. Only six patients (6%) required a new permanent pacemaker. Post-procedural mean pressure gradient was 5.44 ± 2.38 mmHg. None of the treated patients experienced coronary artery occlusion. Cerebrovascular complication (transient and non-disabling) was noted in one patient. Conclusion: In patients with native symptomatic severe aortic stenosis, TAVI using novel, next-generation, ballon-expandable Myval THV offers a safe and reliable treatment option with good procedural success and survival rates and fewer complications.

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Included in

Cardiology Commons